HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
INSIDE INDUSTRY
Mundipharma signs exclusive agreement with Helsinn Group for distribution of Anamorelin® across key markets in SEA

Mundipharma has entered a license agreement with Helsinn for the exclusive rights to develop, manufacture and commercialise Anamorelin®, a novel compound for the treatment of weight loss in cancer patients suffering from Non-Small Cell Lung Cancer (NSCLC) across the ten markets of Singapore, Indonesia, Malaysia, the Philippines, Brunei, Myanmar, Cambodia, Laos, Thailand and Vietnam.

Anamorelin® is a synthetic, orally active ghrelin receptor agonist that shows promise to treat cancer anorexia-cachexia in patients suffering from NSCLC. Attributed to about one-third of cancer deaths, cancer anorexia-cachexia syndrome (CACS) is a disorder that is mainly characterized by muscle atrophy and subsequent cancer induced weight loss (CIWL).

Studies have shown that there is a high correlation between CIWL and early deaths for cancer patients, with a significantly higher number of early deaths reported for patients who lost more than 5% of their body weight as compared to those who lost less than 5% of their body weight. It is estimated that over 50% of late-stage cancer patients suffer from cancer anorexia-cachexia and CIWL as a result. With no truly effective treatment available in the market today, products such as Anamorelin® will play a significant role in meeting the needs of this substantial number of patients.

"We are excited to further expand our partnership with Helsinn and supplement our portfolio of products for supportive care of patients with cancer," said Raman Singh, Regional Managing Director of Mundipharma Asia Pacific, Latin America, Middle East and Africa. "This partnership will help us in our mission to alleviate the burden of pain for cancer patients in the key markets where we operate."

Anamorelin® is currently undergoing two phase III studies, ROMANA 1 and ROMANA 2, which are running in parallel, to evaluate the efficacy of the drug in the treatment of CACS. Both of these trials are expected to complete by the end of 1H 2014.

"This partnership is another step in what we foresee as a long and fruitful association with Mundipharma. We are confident that Anamorelin® will present an important advancement in the management of cancer anorexia-cachexia," said Dr Riccardo Braglia, CEO, Helsinn Group.

Click here for the complete issue.

NEWS CRUNCH  
news Medical technology experts to address the impact of innovation in shaping patient outcomes across Asia Pacific
news China biotech's 'coming out party' masks long road ahead
news SingHealth, Duke NUS and GSK to conduct large-scale big data study on asthma and COPD in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy